WaVe Life Sciences Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Public

  • Employees
  • 317

Employees

  • Stock Symbol
  • WVE

Stock Symbol

  • Share Price
  • $3.13
  • (As of Friday Closing)

WaVe Life Sciences General Information

Description

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Contact Information

Formerly Known As
Ontorii
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 733 Concord Avenue
  • Cambridge, MA 02138
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 733 Concord Avenue
  • Cambridge, MA 02138
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

WaVe Life Sciences Stock Performance

As of 13-Nov-2026, WaVe Life Sciences’s stock price is $3.13. Its current market cap is $617M with 197M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.13 $3.15 $3.00 - $21.73 $617M 197M 3.16M -$1.08

WaVe Life Sciences Financials Summary

As of 30-Sep-2026, WaVe Life Sciences has a trailing 12-month revenue of $70.9M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 282,066 2,989,346 1,610,766 503,245
Revenue 70,921 42,727 108,302 113,305
EBITDA (201,307) (195,526) (88,345) (48,984)
Net Income (210,533) (204,378) (97,008) (57,513)
Total Assets 507,930 638,499 352,207 274,949
Total Debt 43,271 17,766 25,404 32,118
Public Fundamental Data provided by Morningstar, Inc. disclaimer

WaVe Life Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore WaVe Life Sciences‘s full profile, request access.

Request a free trial

WaVe Life Sciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicin
Drug Discovery
Cambridge, MA
317 As of 2025

Waltham, MA
 

Berkeley, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

WaVe Life Sciences Competitors (75)

One of WaVe Life Sciences’s 75 competitors is Dyne Therapeutics, a Formerly VC-backed company based in Waltham, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dyne Therapeutics Formerly VC-backed Waltham, MA
Caribou Biosciences Formerly VC-backed Berkeley, CA
Intellia Therapeutics Formerly VC-backed Cambridge, MA
CRISPR Therapeutics Formerly VC-backed Zug, Switzerland
Capricor Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 75 competitors. Get the full list »

WaVe Life Sciences Patents

WaVe Life Sciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026213595-A1 Oligonucleotide compositions and methods thereof Pending 03-Apr-2025
WO-2026213596-A1 Oligonucleotide compositions and methods thereof Pending 03-Apr-2025
WO-2026213596-A8 Oligonucleotide compositions and methods thereof Pending 03-Apr-2025
WO-2026193338-A1 Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto Pending 13-Mar-2025
WO-2026193338-A8 Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto Pending 13-Mar-2025
To view WaVe Life Sciences’s complete patent history, request access »

WaVe Life Sciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

WaVe Life Sciences ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

41.36 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view WaVe Life Sciences’s complete esg history, request access »

WaVe Life Sciences FAQs

  • When was WaVe Life Sciences founded?

    WaVe Life Sciences was founded in 2012.

  • Where is WaVe Life Sciences headquartered?

    WaVe Life Sciences is headquartered in Cambridge, MA.

  • What is the size of WaVe Life Sciences?

    WaVe Life Sciences has 317 total employees.

  • What industry is WaVe Life Sciences in?

    WaVe Life Sciences’s primary industry is Drug Discovery.

  • Is WaVe Life Sciences a private or public company?

    WaVe Life Sciences is a Public company.

  • What is WaVe Life Sciences’s stock symbol?

    The ticker symbol for WaVe Life Sciences is WVE.

  • What is the current stock price of WaVe Life Sciences?

    As of 13-Nov-2026 the stock price of WaVe Life Sciences is $3.13.

  • What is the current market cap of WaVe Life Sciences?

    The current market capitalization of WaVe Life Sciences is $617M.

  • What is WaVe Life Sciences’s current revenue?

    The trailing twelve month revenue for WaVe Life Sciences is $70.9M.

  • Who are WaVe Life Sciences’s competitors?

    Dyne Therapeutics, Caribou Biosciences, Intellia Therapeutics, CRISPR Therapeutics, and Capricor Therapeutics are some of the 75 competitors of WaVe Life Sciences.

  • What is WaVe Life Sciences’s annual earnings per share (EPS)?

    WaVe Life Sciences’s EPS for 12 months was -$1.08.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process